HCPLive Network

Cadaveric Growth Hormone Does Not Appear to Transmit Alzheimer’s, Parkinson’s Disease

cadaveric growth hormone does not transmit Alzheimer's disease or Parkinson's diseaseTUESDAY, Feb. 5 (HealthDay News) -- There seems to be no evidence to support human-to-human transmission of Alzheimer's disease (AD) or Parkinson's disease (PD) via transmission of neurodegenerative disease (ND)-associated proteins (NDAPs) in recipients of cadaveric human growth hormone (c-hGH), according to a study published online Feb. 4 in JAMA Neurology.

Noting the growing evidence of cell-to-cell transmission of NDAPs, David J. Irwin, M.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues examined evidence for human-to-human transmission of AD, PD, and related NDAPs in 34 routine autopsy subjects (10 non-ND controls and 24 patients with ND) and among recipients of c-hGH in the U.S. National Hormone and Pituitary Program (NHPP) cohort.

In ND and control patients, the researchers identified mild amounts of pathological tau, amyloid-β, and α-synuclein deposits in the adeno/neurohypophysis. Among U.S. NHPP c-hGH recipients, there were no cases of AD or PD; three deaths were attributed to amyotrophic lateral sclerosis.

"In this unique in vivo model of human-to-human transmission, we found no evidence to support concerns that NDAPs underlying AD and PD transmit disease in humans despite evidence of their cell-to-cell transmission in model systems of these disorders," the authors write. "Further monitoring is required to confirm these conclusions."

Two authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
Study finds link between autoimmune skin disease and several neurologic disorders, including dementia, MS, epilepsy, and Parkinson's disease.
Although vitamin C intake has no effect, greater total major carotenoid intake is inversely associated with the risk of amyotrophic lateral sclerosis, according to research published online Jan. 29 in the Annals of Neurology.
A protein released from damaged motor neurons, the phosphorylated neurofilament heavy subunit, may be a useful biomarker for disease activity and progression in patients with amyotrophic lateral sclerosis, according to a study published online Oct. 31 in the Journal of Neurology, Neurosurgery & Psychiatry.
Study results suggest that oxidative stress may play a direct role in the neurodegeneration that occurs in ALS.
Study results show that treatment with riluzole did not slow the rate of brain atrophy and did not demonstrate a detectable neuroprotective effect in patients with early RRMS.
Literature review by the AAN shows that oral and oral spray forms of medical marijuana effectively treat some symptoms of MS, but there is little evidence to support efficacy in treating other neurologic diseases such as Parkinson’s disease, epilepsy, and Tourette syndrome.
More Reading